NANOG and hepatocellular carcinoma: Nevertheless, inhibition of proteasome‐mediated protein degradation could not prevent TARBP2‐mediated Nanog degradation, suggesting that the degradation of the TARBP2 protein in HCC/SR cells is lysosome‐dependent (Fig. 6H).